1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 26, 01/Jul/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.26.2100533
2021-07-01
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.26.2100533
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/26/eurosurv-26-26-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.26.2100533&mimeType=html&fmt=ahah

References

  1. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91.  https://doi.org/10.1016/S0140-6736(21)00432-3  PMID: 33617777 
  2. European Medicines Agency (EMA). Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events. Amsterdam: EMA; 7 Apr 2021. Available from: https://www.ema.europa.eu/en/events/press-briefing-conclusion-assessment-pharmacovigilance-risk-assessment-committee-prac-vaxzevria
  3. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208-11.  https://doi.org/10.1126/science.abc3517  PMID: 32404476 
  4. Tran Kiem C, Massonnaud C, Levy-Bruhl D, Poletto C, Colizza V, Bosetti P, et al. Short and medium-term challenges for COVID-19 vaccination: from prioritisation to the relaxation of measures. Paris: HAL-Pasteur; 2021. Preprint. Available from: https://hal-pasteur.archives-ouvertes.fr/pasteur-03190243
  5. Santé publique France. Données hospitalières relatives à l’épidémie de COVID-19. [Hospital data relating to the COVID-19 epidemic]. Saint-Maurice: Santé publique France. [Accessed: 29 Jun 2021]. French. Available from: https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19
  6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  8. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.  https://doi.org/10.1056/NEJMoa2101544  PMID: 33882225 
  9. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459-69.  https://doi.org/10.1016/S0140-6736(21)00675-9  PMID: 33844963 
  10. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  11. Santé publique France. Données relatives aux personnes vaccinées contre la Covid-19. [Data relating to people vaccinated against COVID-19]. ]. Saint-Maurice: Santé publique France. [Accessed: 29 Jun 2021]. French. Available from: https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1
  12. European Medicines Agency (EMA). Assessment report. Procedure under Article 5(3) of Regulation (EC) No 726/2004. Invented name: Vaxzevria. Amsterdam: EMA; 23 Apr 2021. Available from: https://www.ema.europa.eu/en/documents/referral/use-vaxzevria-prevent-covid-19-article-53-procedure-assessment-report_en.pdf
  13. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202-11.  https://doi.org/10.1056/NEJMoa2105385  PMID: 33861525 
  14. Collège de la Haute Autorité de Santé (HAS). Avis n°2021.0032/AC/SEESP du 12mai 2021 du collège de la Haute Autorité de santé relatif aux vaccins à adénovirus suite aux nouvelles données disponibles sur la balance bénéfice/risque par tranche d’âge dans le contexte français. [Opinion no. 2021.0032/AC/SEESP of 12 May 2021 from the Collège of the Haute Autorité de santé relating to adenovirus vaccines following new data available on the benefit–risk balance by age group in the French context. Saint-Denis: HAS; 2021. French. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2021-05/ac_2021_0032_avis_population_cible_vaccins_adenovirus_cd_2021_05_12_vd.pdf
  15. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140-5.  https://doi.org/10.1038/s41586-020-2918-0  PMID: 33137809 
  16. Winton Centre Cambridge. News - Latest data from the MHRA on blood clots associated with the Astra Zeneca COVID-19 vaccine. Cambridge: Winton Centre. [Accessed: 27 May 2021]. Available from: https://wintoncentre.maths.cam.ac.uk/news/latest-data-mhra-blood-clots-associated-astra-zeneca-covid-19-vaccine
  17. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-98.  https://doi.org/10.1056/NEJMoa2102214  PMID: 33725432 
  18. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. Lancet. 2011;378(9790):526-35.  https://doi.org/10.1016/S0140-6736(11)60678-8  PMID: 21664679 
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=C%C3%A9cile+Tran+Kiem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tran Kiem Cécile</a>, <a href="/search?value1=Alessio+Andronico&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Andronico Alessio</a>, <a href="/search?value1=Paolo+Bosetti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bosetti Paolo</a>, <a href="/search?value1=Juliette+Paireau&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Paireau Juliette</a>, <a href="/search?value1=Lise+Alter&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Alter Lise</a>, <a href="/search?value1=Pierre-Yves+Bo%C3%ABlle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Boëlle Pierre-Yves</a>, <a href="/search?value1=Arnaud+Fontanet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fontanet Arnaud</a>, <a href="/search?value1=Daniel+L%C3%A9vy-Bruhl&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lévy-Bruhl Daniel</a>, <a href="/search?value1=Simon+Cauchemez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cauchemez Simon</a></span>. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(26):pii=2100533. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100533" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100533</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 31 May 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 30 Jun 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.26.2100533
/content/10.2807/1560-7917.ES.2021.26.26.2100533
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error